



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026

Sr.No.	Particulars	Quarter ended 30-06-2026	Quarter ended 31-03-2026	Quarter ended 30-06-2025	Year ended 31-03-2026
		Unaudited	Audited	Unaudited	Audited
	Income				
I	Revenue from Operations	1,897.47	2,765.28	1,450.74	8,278.75
II	Other Income	26.48	34.78	26.74	114.87
III	Total Income	1,923.95	2,800.06	1,477.48	8,393.62
	Expenses				
	a) Cost of Materials Consumed	1,094.00	833.61	437.76	2,651.18
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	(530.15)	219.66	(120.04)	(110.89)
	d) Employee benefit expenses	284.90	248.17	226.88	966.80
	e) Finance Cost	3.74	4.68	5.12	18.89
	f) Depreciation & amortisation expense	89.40	84.98	64.51	284.09
	g) Other expenditure	574.14	487.67	389.13	1,831.18
IV	Total Expenses	1,516.03	1,878.77	1,003.36	5,641.25
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	407.92	921.29	474.12	2,752.37
VI	Exceptional Items	-	-	-	(4.58)
VII	Profit/(loss) before Tax (V-VI)	407.92	921.29	474.12	2,747.79
VIII	Tax Expense				
	a) Current Tax	85.13	204.16	105.35	614.33
	b) Deferred Tax	82.36	(25.16)	20.87	42.26
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	240.43	742.29	347.90	2,091.20
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	240.43	742.29	347.90	2,091.20
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	8.65	0.55	(2.87)	(1.33)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(2.18)	(0.14)	0.72	0.34
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	246.90	742.70	345.75	2,090.21
XVI	Earnings per equity Share (for continuing operation):				
	(1) Basic (In ₹)	2.99	9.22	4.32	25.98
	(2) Diluted (In ₹)	2.99	9.22	4.32	25.98
XVII	Earnings per equity Share (for discontinued operation):				
	(1) Basic (In ₹)	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):				
	(1) Basic (In ₹)	2.99	9.22	4.32	25.98
	(2) Diluted (In ₹)	2.99	9.22	4.32	25.98

See accompanying notes to the financial statements:

Notes:-

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on August 13, 2026.
- The material dispatched for export was intercepted and detained by Customs and remained in Customs custody as of June 30, 2026. Accordingly, the goods were not part of the Company's closing inventory as of that date. Since the shipment had already reached Customs for export processing, the transaction has been recognized as a sale in the books.
- The company does not have any subsidiary/associate/joint venture company as on June 30, 2026.
- The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Place :- Mumbai

Date :- August 13, 2026